The landscape of AI-driven drug discovery is poised for a significant evaluation in 2026, as a cohort of AI-generated drugs is set to enter critical Phase 3 trials.
In a recent analysis by Michael Santoro, a business ethics professor, the implications of substantial investments in AI for drug discovery are scrutinized. Notable examples include Xaira’s ambitious $1 billion launch and Alphabet’s Isomorphic Labs, which secured $600 million in funding. Santoro references a Boston Consulting Group study highlighting that while AI-discovered drugs achieve an impressive success rate of 80-90% in Phase 1 trials, this rate drops significantly to about 40% in Phase 2 trials, aligning with industry standards. This suggests that, despite early promise, the transition from safety to efficacy remains a challenging hurdle.
Moreover, the overall probability of an AI-discovered drug reaching the market is estimated to increase from 5-10% to 9-18%, primarily benefiting the less costly early trial phases. For instance, Phase 1 trials average around $4 million, whereas Phase 3 can exceed $20 million, contributing to a total drug development cost of approximately $2.6 billion. Santoro highlights Insilico Medicine’s rentosertib as a potential success story, contrasting it with Recursion’s decision to halt its lead AI-discovered program in 2025.
This upcoming evaluation in 2026 will be crucial for the credibility of AI in drug discovery, potentially shaping future investments and strategic directions in the biotech sector.